Bulletin
Investor Alert

Intellia Therapeutics Inc.

NAS: NTLA

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Intellia Therapeutics Inc.

After Hours

NTLA
/zigman2/quotes/207821052/composite

$

39.19

Change

+0.21 +0.54%

Volume

Volume 19,079

May 26, 2023, 7:25 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/207821052/composite

Previous close

$ 39.22

$ 38.98

Change

-0.24 -0.61%

Day low

Day high

$38.01

$39.42

Open
Open: 39.04

52 week low

52 week high

$32.44

$76.45

Open

Market cap

$3.44B

Average volume

1.00M

P/E ratio

N/A

Rev. per Employee

$89,423

EPS

-5.39

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/ntla

MarketWatch News on NTLA

  1. Intellia Therapeutics upgraded to outperform at BMO Capital

    10:18 a.m. March 14, 2023

    - Tomi Kilgore

  4. Intellia Therapeutics stock price target cut to $131 from $173 at Stifel Nicolaus

    8:49 a.m. Jan. 6, 2023

    - Tomi Kilgore

  5. Intellia Therapeutics started at overweight with $84 stock price target at Morgan Stanley

    9:41 a.m. Oct. 11, 2022

    - Tomi Kilgore

  6. What’s Next for the Healthcare Industry, and How to Invest

    9:47 a.m. Sept. 25, 2022

    - Barron's Online

  9. 11 Cheap Tech Stocks to Consider After the Earnings Deluge

    4:32 p.m. Aug. 25, 2022

    - Barron's Online

  10. 10 Stocks Driving the Biotech Resurgence

    8:49 a.m. Aug. 18, 2022

    - Barron's Online

  11. Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead

    4:25 p.m. June 23, 2022

    - Barron's Online

  12. Intellia Therapeutics started at market perform with $54 stock price target at BMO Capital

    12:22 p.m. June 17, 2022

    - Tomi Kilgore

  16. Intellia Therapeutics upgraded to outperform from perform at Oppenheimer

    8:28 a.m. Feb. 7, 2022

    - Tomi Kilgore

  19. Beam Gets FDA Nod for First Gene-Editing Trial

    9:10 a.m. Nov. 9, 2021

    - Barron's Online

  20. Prime Is the Newest Gene Editing, and It's Getting Better

    7:11 p.m. Oct. 20, 2021

    - Barron's Online

  21. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/ntla

Other News on NTLA

  1. 10-Q: INTELLIA THERAPEUTICS, INC.

    4:18 p.m. May 4, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  2. 10-K: INTELLIA THERAPEUTICS, INC.

    5:14 p.m. Feb. 23, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  4. Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss

    1:20 p.m. Nov. 4, 2022

    - Zacks.com

/news/pressrelease/company/us/ntla

Press Releases on NTLA

  4. Intellia Therapeutics Names Bill Chase to its Board of Directors

    4:01 p.m. April 17, 2023

    - GlobeNewswire

  5. SparingVision appoints Joseph C. Papa as Chairman

    7:00 a.m. April 5, 2023

    - GlobeNewswire

Rates »

Mortgage Equity Savings Auto
Link to MarketWatch's Slice.